Table 4 Concordance of NCCN-recommended molecular targets detected by both FoundationACT and FoundationOne assays in 42 patients with advanced solid tumors
Tumor types | Genomic alterations | No. concordance (N = 22) | No. unique to FoundationOne (N = 4) | % concordance (N = 26) | No. unique to FoundationACT (N = 8) |
|---|---|---|---|---|---|
NSCLC (N = 33) | EGFR L858R and exon 19 deletions | 8 | 2 | 80% | 0 |
EGFR T790Â M | 2 | 1 | 67% | 0 | |
ALK rearrangements | 4 | 0 | 100% | 0 | |
BRAF V600 mutation | 1 | 0 | 100% | 0 | |
MET exon 14 skip site alterations | 2 | 1 | 67% | 0 | |
ERBB2 mutations | 0 | 0 | 100% | 2 | |
Breast (N = 7) | ERBB2 amplification or mutation | 1 | 0 | 100% | 1 |
BRCA1/2 mutations | 2 | 0 | 100% | 4 | |
Ovarian (N = 2) | BRCA1/2 mutations | 2 | 0 | 100% | 0 |